GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » Ending Cash Position

Geron (GERN) Ending Cash Position : $80.88 Mil (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Geron Ending Cash Position?

Geron's Ending Cash Position for the quarter that ended in Dec. 2024 was $80.88 Mil.

Geron's quarterly Ending Cash Position declined from Jun. 2024 ($118.07 Mil) to Sep. 2024 ($62.20 Mil) but then increased from Sep. 2024 ($62.20 Mil) to Dec. 2024 ($80.88 Mil).

Geron's annual Ending Cash Position increased from Dec. 2022 ($57.21 Mil) to Dec. 2023 ($71.14 Mil) and increased from Dec. 2023 ($71.14 Mil) to Dec. 2024 ($80.88 Mil).

Geron Ending Cash Position Historical Data

The historical data trend for Geron's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Ending Cash Position Chart

Geron Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.29 35.24 57.21 71.14 80.88

Geron Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.14 190.88 118.07 62.20 80.88

Geron Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Geron's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=71.138+9.738
=80.88

Geron's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=62.198+18.678
=80.88

Geron Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Geron's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » Ending Cash Position
Comparable Companies
ELVN SYRE MDXG NVAX SNDX AUPH INVA ADPT IOVA ARDX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0IV3:UK GON:Germany GON:Germany
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Website
https://www.geron.com
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Executives
Scott Alan Samuels officer: EVP, Chief Legal Officer 919 E. HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
John A Scarlett director, officer: Chief Executive Officer C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Andrew J Grethlein officer: EVP, Technical Operations 651 GATEWAY BLVD STE 950, SOUTH SAN FRANCISCO CA 94080
Faye Feller officer: EVP, Chief Medical Officer 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA 94404
Anil Kapur officer: EVP, Corp Strategy & CCO 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Michelle Robertson officer: EVP, Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
V Bryan Lawlis director
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Olivia Kyusuk Bloom officer: Controller, Chief Acctg Off C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
John F Mcdonald director C/O GERON CORPORATION, 919 EAST HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
Melissa Kelly officer: VP, Oncology 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Dawn Carter Bir director C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Aleksandra Rizo officer: EVP, Chief Medical Officer C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025